Impulsive aggression: recognition and choice of pharmacotherapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Instrumental (controlled) aggression is observed in populations of both mentally healthy and mentally ill people. This type of aggression is not associated with any specific pathophysiological changes and cannot be considered as an independent symptom, which might be a target of pathogenetic therapy. By contrast, impulsive aggression is a paroxysm of anger, based on affectively narrowed consciousness when volition control is significantly reduced or absent. Impulsivity is different from cognate compulsivity by the loss of a stage of intellectual processing of affectively painted representations and by that the irrational attraction to action is realized involuntary, automatic. All impulsive-behavior patients are united by common pattern of neurobiological abnormalities, such as deficit of frontal inhibition of subcortical unconscious emotions and inclinations in response to relevant arousing stimuli. The results from evidence-based research, meta-analyses and Cochrane reviews of efficiency of pharmacological agents used for reduction of impulsive aggressive behavior were summarized.

Full Text

Restricted Access

About the authors

Evgeny V. Snedkov

St. Nicholas Psychiatric Hospital; I.I. Mechnikov North-West State Medical University

Author for correspondence.
Email: esnedkov@mail.ru

Department of Psychiatry and Addiction

Russian Federation, 190121, St. Petersburg, Moika River, 126; Санкт-Петербург

References

  1. Рубинштейн С.Л. Основы общей психологии. 2-е изд. (1946 г.). СПб, 2002. 720 с.
  2. Снедков Е.В., Бадри К. Факторы, сопряженные с результатами применения антипсихотиков при лечении больных шизофренией // Российский психиатрический журнал. 2007. №5. С. 83‒89.
  3. Снедков Е.В. Страсти по психопатии (продолжение обсуждения статьи В.Д. Менделевича) // Неврологический вестник. 2017. Т. XLIX, вып. 3. С. 92‒98.
  4. Снедков Е.В. Стресс и аддикции // Школа В.М. Бехтерева: от истоков до современности: материалы Все- российской научно-практ. конф. с междунар. участием. [Электронное издание]. СПб: Альта Астра, 2017. С. 345‒347.
  5. Aaronson A., Brett Lloyd R. Aggression after traumatic brain injury: a review of the current literature // Psychiatr Ann. 2015. Vol. 45(8). P. 422–426.
  6. Allen T.J., Moeller F.G., Rhoades H.M., Cherek D.R. Impulsivity and history of drug dependence // Drug Alcohol Depend. 1998. Vol. 50(2). P. 137‒145.
  7. Amen D.G., Stubblefield M., Carmicheal B. Brain SPECT findings and aggressiveness // Ann Clin Psychiatry. 1996. Vol. 8(3). P. 129–137.
  8. Apter A., van Praag H.M., Plutchik R. et al. Interrelationships among anxiety, aggression, impulsivity, and mood: a serotonergically linked cluster? // Psychiatry Res. 1990. Vol. 32(2). P. 191‒199.
  9. Aron A.R., Dowson J.H., Sahakian B.J., Robbins T.W. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder // Biol Psychiatry. 2003. Vol. 54(12). P. 1465‒1468.
  10. Ballard C., Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer’s disease // Cochrane Database Syst Rev. 2006. Vol. 1:CD003476.
  11. Barratt E.S., Stanford M.S., Felthous A.R. et al: The effects of phenytoin on impulsive and premeditated aggression: a controlled study // J Clin Psychopharmacol. 1997. Vol. 17(5). P. 341‒349.
  12. Barratt E.S., Stanford M.S., Kent T.A., Felthous A.R. Neuropsychological and cognitive psychophysiological substrates of impulsive aggression // Biol Psychiatry. 1997. Vol. 41(10). Р. 1045‒1061.
  13. Bechara A: Neurobiology of decision-making: risk and reward // Semin Clin Neuropsychiatry. 2001. Vol. 6(3). P. 205‒216.
  14. Bidzan L., Grabowski J., Dutczak B., Bidzan M. [Impact of treatment with acetylcholinesterase inhibitors, valproic acid and antipsychotics on aggressive behaviour in Alzheimer’s type dementia]. [Article in Polish] // Psychiatr Pol. 2012. Vol. 46(3). P. 361‒372.
  15. Biederman J., Mick E., Surman C. et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder // Biol Psychiatry 2006. Vol. 59(9). P. 829‒835.
  16. Bilder R.M., Volavka J., Lachman H.M., Grace A.A. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes // Neuropsychopharmacology. 2004. Vol. 29(11). P. 1943‒1961.
  17. Brambilla P., Bellani M., Yeh P.H. et al. White matter connectivity in bipolar disorder // Int Rev Psychiatry. 2009. Vol. 21(4). P. 380–386.
  18. Bremner J.D., Southwick S.M., Darnell A., Charney D.S. Chronic PTSD in Vietnam combat veterans: course of illness and substance abuse // Am J Psychiatry. 1996. Vol. 153(3). P. 369‒375.
  19. Brodaty H., Ames D., Snowdon J. et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia // J Clin Psychiatry. 2003. Vol. 64(2). P. 134‒143.
  20. Brodie M.J., Besag F., Ettinger A.B. et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based reviews // Pharmacol Rev. 2016. Vol. 68(3). P. 563‒602.
  21. Brown E.S., Nejtek V.A., Perantie D.C. et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation // J Clin Psychopharmacol. 2003. Vol. 23(4). P. 384‒388.
  22. Buckley P., Bartell J., Donenwirth K. et al. Violence and schizophrenia: clozapine as a specific antiaggressive agent // Bull Am Acad Psychiatry Law. 1995. Vol. 23(4). P. 607‒611.
  23. Bukstein O.G., Kolko D.J. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder // J Clin Child Psychol. 1998. Vol. 27(3). P. 340‒351.
  24. Caspi N., Modai I., Barak P. et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study // Int Clin Psychopharmacol. 2001. Vol. 16(2). P. 111‒115.
  25. Chamberlain S.R., Sahakian B.J. The neuropsychiatry of impulsivity. Curr Opin Psychiatry. 2007. Vol. 20(3). P. 255‒261.
  26. Chen J., LipskaB.K., Halim N. et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain // Am J Hum Genet. 2004. Vol. 75(5). P. 807–821.
  27. Cipriani A., Reid K., Young A.H. et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder // Cochrane Database Syst Rev. 2013. (10): CD003196.
  28. Cipriani A., Rendell J.M., Geddes J. Olanzapine in long-term treatment for bipolar disorder // Cochrane Database Syst Rev. 2009. (1): CD004367.
  29. Citrome L., Casey D.E., Daniel D.G. et al. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone // Psychiatr Serv. 2004. Vol. 55(3). P. 290‒294.
  30. Citrome L., Volavka J., Czobor P. et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia // Psychiatr Serv. 2001. Vol. 52. P. 1510‒1514.
  31. Citrome L., Volavka J. Schizophrenia: Violence and comorbidity // Curr Opin Psychiatry. 1999. Vol. 12(1). P. 47‒51.
  32. de Clérambault G.G. Syndrome mécanique et conception mécanisiste des psychoses hallucinatoires // Annales médico-psychologiques. Paris, 1927. Vol. 85. P. 398‒413.
  33. Coccaro E.F. Intermittent explosive disorder as a disorder of impulsive aggression for DSM-5 // Am J Psychiatry. 2012. Vol. 169(6). P. 577‒588.
  34. Coccaro E.F., Lee R.J., Kavoussi R.J. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder // J Clin Psychiatry. 2009. Vol. 70(5). P. 653‒662.
  35. Coccaro E.F., Lee R., Vezina P. Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects // J Psychiatr Res. 2013. Vol. 47(9). P. 1247‒1253.
  36. Coccaro E.F., McCloskey M.S., Fitzgerald D.A., Phan K.L. Amygdala and orbitofrontal reactivity to social threat in individuals with impulsive aggression // Biol Psychiatry. 2007. Vol. 62(2). P. 168‒178.
  37. Coccaro E.F., Posternak M.A., Zimmerman M. Prevalence and features of intermittent explosive disorder in a clinical setting // J Clin Psychiatry. 2005. Vol. 66(10). P. 1221‒1227.
  38. Comai S., Tau M., Gobbi G. The psychopharmacology of aggressive behavior: a translational approach. Part 1: Neurobiology // J Clin Psychopharmacol. 2012. Vol. 32(1). P. 83‒94.
  39. Comai S., Tau M., Pavlovic Z., Gobbi G. The psychopharmacology of aggressive behavior: A translational approach. Part 2: Clinical studies using atypical antipsychotics, anticonvulsants, and lithium // J Clin Psychopharmacol. 2012. Vol. 32(2). P. 237‒260.
  40. Connor D.F. Beta blockers for aggression: a review of the pediatric experience // J Child Adolesc Psychopharmacol. 1993. Vol. 3(2). P. 99‒114.
  41. Conrod P.J., Castellanos-Ryan N., Strang, J. Brief, personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period during adolescence // Arch Gen Psychiatry. 2010. Vol. 67(1). P. 85–93.
  42. Corruble E., Damy C., Guelfi J.D. Impulsivity: a relevant dimension in depression regarding suicide attempts? // J Affect Disord. 1999. Vol. 53(3). P. 211‒215.
  43. Cowdry R.W., Gardner D.L. Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluroperazine, and tranylcypromine // Arch Gen Psychiatry.1988. Vol. 45(2). P. 111‒119.
  44. Craddock N., Owen M.J., O’Donovan M.C. The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons // Mol Psychiatry. 2006. Vol. 11(5). P. 446‒458.
  45. Craft M., Ismail I.A., Krishnamurti D. et al. Lithium in the treatment of aggression in mentally handicapped patients: a double-blind trial // Br J Psychiatry. 1987. Vol. 150. P. 685‒689.
  46. Crews F.T., Collins M.A., Dlugos C. et al. Alcohol-induced neurodegeneration: when, where and why? // Alcohol Clin Exp Res. 2004. Vol. 28(2). P. 350–364.
  47. Cumbo E., Ligori L.D. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: a 12-month, randomized, open-label trial // J Alzheimers Dis. 2014. Vol. 39(3). P. 477‒485.
  48. Czobor P., Volavka J., Meibach R.C. Effect of risperidone on hostility in schizophrenia // J Clin Psychopharmacol. 1995. Vol. 15(4). P. 243‒249.
  49. Dale P.G. Lithium therapy in aggressive mentally subnormal patients // Br J Psychiatry. 1980. Vol. 137. P. 469‒474.
  50. Dalley J.W., Everitt B.J., Robbins T.W. Impulsivity, compulsivity, and top-down cognitive control // Neuron. 2011. Vol. 69(4). P. 680‒694.
  51. Davanzo P., Yue K., Thomas M.A. et al. Proton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents // Am J Psychiatry. 2003. Vol. 160(8). P. 1442‒1452.
  52. Davis W.M. Psychopharmacologic violence associated with cocaine abuse: kindling of a limbic dyscontrol syndrome? // Prog Neuropsychopharmacol. Biol Psychiatry. 1996. Vol. 20(8). P. 1273‒1300.
  53. Donovan S.J., Stewart J.W., Nunes E.V. et al. Divalproex treatment for a youth with explosive temper and mood lability: a double-blind placebo-controlled crossover design // Am J Psychiatry. 2000. Vol. 157(5). P. 818‒820.
  54. Doran N., Spring B., McChargue D. Effect of impulsivity on craving and behavioral reactivity to smoking cues // Psychopharmacology. 2007. Vol. 194(2). P. 279–288.
  55. Elie R., Langlois Y., Cooper S.F. et al. Comparison of SCH-12679 and thioridazine in aggressive mental retardates // Can J Psychiatry. 1980. Vol. 25(6). P. 484‒491.
  56. Enman N.M., Zhang Y., Unterwald E.M. Connecting the pathology of posttraumatic stress and substance use disorders: monoamines and neuropeptides // Pharmacol Biochem Behav. 2014. Vol. 117. P. 61‒69.
  57. Fan J.B., Zhang C.S., Gu N.F. et al. Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: a large-scale association study plus meta-analysis // Biol Psychiatry. 2005. Vol. 57(2). P. 139–144.
  58. Felthous A.R., Stanford M.S. A proposed algorithm for the pharmacotherapy of impulsive aggression // J Am Acad Psychiatry Law. 2015. Vol. 43(4). P. 456‒467.
  59. Fesler F.A. Valproate in combat related posttraumatic stress disorder // J Clin Psychiatry. 1991. Vol. 52(9). P. 361‒363.
  60. Finkel S.I., Mintzer J.E., Dysken M. et al. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer’s disease in outpatients treated with donepezil // Int J Geriatr Psychiatry. 2004. Vol. 19(1). P. 9‒18.
  61. Frankenburg F.R., Zanarini M.C. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind, placebo controlled pilot study // J Clin Psychiatry. 2002. Vol. 63(5). P. 442‒446.
  62. Frankle W.G., Lombardo I., New A.S. et al. Brain serotonin transporter distribution in subjects with impulsive aggressivity a positron emission study with [11C]McN 5652 // Am J Psychiatry. 2005. Vol. 162(5). P. 915‒923.
  63. Gadow K.D., Nolan E.E., Sverd J. et al. Methylphenidate in aggressive-hyperactive boys: I. Effects on peer aggression in public school settings // J Am Acad Child Adolesc Psychiatry. 1990. Vol. 29(5). P. 710‒718.
  64. Gareri P., Putignano D.,Castagna A. et al. Retrospective study on the benefits of combined memantine and cholinesterase inhibitor treatment in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study // J Alzheimers Dis. 2014. Vol. 41(2). P. 633‒640.
  65. Giancola P.R. Evidence for dorsolateral and orbital prefrontal cortical involvement in the expression of aggressive behavior // Aggress Behav1995. Vol. 21 P. 431‒450.
  66. Gilpin N.W., Weiner, J.L. Neurobiology of comorbid post-traumatic stress disorder and alcohol-use disorder // Genes Brain Behav. 2017. Vol. 16(1). P. 15–43.
  67. Gobbi G., Debonnel G. What is a recommended treatment for aggression in a patient with schizophrenia? // J Psychiatry Neurosci. 2003. Vol. 28(4). P. 320.
  68. Goldberg S.C., Schulz S.C., Schulz P.M. et al. Borderline and schizotypal personality disorders treated with low-dose thiothixene versus placebo // Arch Gen Psychiatry.1986. Vol. 43(7). P. 680‒686.
  69. Goldberg T.E., Egan M.F., Gscheidle T. et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia // Arch Gen Psychiatry. 2003. Vol. 60(9). P. 889–896.
  70. Goodman M., New A. Impulsive aggression in borderline personality disorder // Curr Psychiatry Rep. 2000. Vol. 2(1). P. 56‒61.
  71. Gorman E.B., Klorman R., Thatcher J.E., Borgstedt A.D. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder // J Am Acad Child Adolesc Psychiatry. 2006. Vol. 45(7). P. 808‒816.
  72. Grace A.A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia // Neuroscience. 1991. Vol. 41(1). P. 1‒24.
  73. Greendyke R.M., Kanter D.R., Schuster D.B. et al. Propranolol treatment of assaultive patients with organic brain disease: a double-blind crossover, placebo-controlled study // J Nerv Ment Dis. 1986. Vol. 174(5). P. 290‒294.
  74. Gröpper S., Spengler S., Stuke H. et al. Behavioral impulsivity mediates the relationship between decreased frontal gray matter volume and harmful alcohol drinking: A voxel-based morphometry study // J Psychiatr Res. 2016. Vol. 83. P. 16‒23.
  75. Haass-Koffler C.L., Leggio L., Kenna G.A. Pharmaco-logical approaches to reducing craving in patients with alcohol use disorders // CNS Drugs. 2014. Vol. 28(4). P. 343–360.
  76. Haile C.N., Kosten T.R., Kosten T.A. Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine // Am J Drug Alcohol Abuse. 2009. Vol. 35(3). P. 161‒177.
  77. Hamidovic A., Dlugos A., Skol A. et al. Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants // Exp Clin Psychopharmacol. 2009. Vol. 17(6). P. 374‒383.
  78. Hermans E.J., Ramsey N.F., van Honk T.V. Exogenous testosterone enhances responsiveness to social threat in neural circuitry of social aggression in humans // Biol Psychiatry. 2008. Vol. 63(3). P. 263‒270.
  79. Huband N., Ferriter M., Nathan R. et al. Antiepileptics for aggression and associated impulsivity // Cochrane Database Syst Rev. 2010. (2): CD003499.
  80. Hughes D.H. Acute psychopharmacological management of the aggressive psychotic patient // Psychiatr Serv. 1999. Vol. 50(9). P. 1135‒1137.
  81. Indave B.I., Minozzi S., Pani P.P., Amato L. Antipsychotic medications for cocaine dependence // Cochrane Database Syst Rev. 2007. (3): CD006306.
  82. Jones R.M., Arlidge J., Gilham R. et al. Efficacy of mood stabilizers in the treatment of impulsive or repetitive aggression: systemic review and meta-analysis // Br J Psychiatry. 2011. Vol. 198(2). P. 93‒98.
  83. Joukamaa M., Helliovaara M., Knekt P. et al. Schizophrenia, neuroleptic medication and mortality // Br J Psychiatry. 2006. Vol. 188. P. 122‒127.
  84. Kalivas P.W., Volkow N.D. The neural basis of addiction: a pathology of motivation and choice // Am. J. Psychiatry. 2005. Vol. 162(8). P. 1403‒1413.
  85. Kanemoto K., Tadokoro Y., Oshima T. Violence and postictal psychosis a comparison of postictal psychosis, interictal psychosis, and postictal confusion // Epilepsy Behav. 2010. Vol. 19(2). P. 162‒166.
  86. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia // Am J Psychiatry. 1999. Vol. 156(2). P. 286‒293.
  87. Kessler R.C., Coccaro E.F., Fava M. et al. The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication // Arch. Gen. Psychiatry. 2006. Vol. 63 (6). P. 669–678.
  88. Kim S., Lee D. Prefrontal cortex and impulsive decision making // Biol. Psychiatry. 2011. Vol. 69(12). P. 1140‒1146.
  89. Kishi T., Matsunaga S., Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer’s disease: a meta-analysis // Neuropsychiatr Dis Treat. 2017. Vol. 13. P. 1909‒1928.
  90. Krakowski M. Violence and serotonin: influence of impulse control, affect regulation, and social functioning // J Neuropsychiatry Clin Neurosci. 2003. Vol. 15(3). P. 294‒305.
  91. Lee G.P., Bechara A., Adolphs R. et al. Clinical and physiological effects of stereotaxic bilateral amygdalotomy for intractable aggression // J Neuropsychiatry Clin Neurosci. 1998. Vol. 10(4). P. 413-420.
  92. Lee R., Arfanakis K., Evia A.M. et al. White matter integrity reductions in intermittent explosive disorder // Neuropsychopharmacology. 2016. Vol. 41(11). P. 2697‒2703.
  93. Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths // Am J Psychiatry. 2011. Vol. 168(2). P. 129–142.
  94. Lindenmayer J.P., Kotsaftis A. Use of sodium valproate in violent and aggressive behaviors: a critical review // J Clin Psychiatry. 2000. Vol. 61(2). P. 123‒128.
  95. Linnoila M., Virkkunen M., Scheinin M. et al. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior // Life Sci. 1983. Vol. 33(26). P. 2609‒2614.
  96. Lohoff F.W., Weller A.E., Bloch P.J. et al. Association between the catechol-O-methyltransferase (COMT) Val158Met polymorphism and cocaine dependence // Neuropsychopharmacology. 2008. Vol. 33(13). P. 3078–3084.
  97. Loy J.H., Merry S.N., Hetrick S.E., Stasiak K. Atypical antipsychotics for disruptive behaviour disorders in children and youths // Cochrane Database Syst Rev. 2017. (8): CD008559.
  98. Macritchie K.A., Geddes J.R, Scott J. et al. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder // Cochrane Database Syst Rev. 2001. (3): CD003196.
  99. Mahon K., Burdick K.E., Wu J. Relationship between suicidality and impulsivity in bipolar I disorder: a diffusion tensor imaging study // Bipolar Disorders. 2012. Vol. 14(1). P. 80–89.
  100. Mann J.J., Waternaux C., Haas G.L., Malone K.M. Toward a clinical model of suicidal behavior in psychiatric patients // Am J Psychiatry. 1999. Vol. 156(2). P. 181‒189.
  101. Marsh L., Krauss G.L. Aggression and violence in patients with epilepsy // Epilepsy Behav. 2000. Vol. 1(3). P. 160‒168.
  102. Martinez D., Kim J.H., Krystal J., Abi-Dargham A. Imaging the neurochemistry of alcohol and substance abuse // Neuroimaging Clin N Am. 2007. Vol. 17(4). P. 539‒555.
  103. Mattes J.A. Oxcarbazepine in patient with impulsive aggression: a double-blind, placebo-controlled trial // J Clin Psychopharmacol. 2005. Vol. 25(6). P. 575‒579.
  104. Maust D.T., Kim H.M., Seyfried L.S. et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm // JAMA Psychiatry. 2015. Vol. 72(5). P. 438‒445.
  105. McCloskey M.S., Berman M.E., Noblett K.L., Coccaro E.F. Intermittent explosive disorder-integrated research diagnostic criteria: convergent and discriminant validity // J Psychiatr Res. 2006. Vol. 40(3). P. 231‒242.
  106. McCown W.G. Multi-impulsive personality disorder and multiple substance abuse: evidence from members of self-help groups // Br J Addict. 1988. Vol. 83(4). P. 431‒432.
  107. McElroy S.L. Recognition and treatment of DSM-IV intermittent explosive disorder // J Clin Psychiatry. 1999. Vol. 60 (Suppl 15). P. 12–16.
  108. Meloy J.R. Empirical basis and forensic application of affective and predatory violence. Aust N Z J Psychiatry. 2006. Vol. 40(6-7). P. 539-547.
  109. Moeller F.G., Barratt E.S., Dougherty D.M. et al. Psychiatric aspects of impulsivity // Am J Psychiatry. 2001. Vol. 158(11). P. 1783‒1793.
  110. Moeller F.G., Dougherty D.M., Barratt E.S. et al. The impact of impulsivity on cocaine use and retention in treatment // J Subst Abuse Treat. 2001. Vol. 21(4). P. 193–198.
  111. Murray-Thomas T., Jones M.E., Patel D. et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the General Practice Research Database // Cardiovasc Psychiatry Neurol. 2013. №64. P. 7476.
  112. Neppe V.M. Carbamazepine as adjunctive treatment in non-epileptic chronic inpatients with EEG temporal lobe abnormalities // J Clin Psychiatry. 1983. Vol. 44(9). P. 326‒331.
  113. New A.S., Buchsbaum M.S., Hazlett E.A. et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression // Psychopharmacology (Berl). 2004. 176(3-4). P. 451‒458.
  114. Olfson M., Blanco C., Liu L. et al. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs // Arch Gen Psychiatry. 2006. Vol. 63(6). P. 679‒685.
  115. Onor M.L., Saina M., Trevisiol M. et al. Clinical experience with risperidone in the treatment of behavioral and psychological symptoms of dementia // Prog Neuropsychopharmacol Biol Psychiatry. 2007. Vol. 31(1). P. 205‒209.
  116. Pandya N.S., Vrbancic M., Ladino L.D., Téllez-Zenteno J.F. Epilepsy and homicide // Neuropsychiatr Dis Treat. 2013. Vol. 9. P. 667‒673.
  117. Paton C. Benzodiazepines and disinhibition: A review // Psych Bulletin. 2002. Vol. 26(12). P. 460‒462.
  118. Perry J.L., Carroll M.E. The role of impulsive behavior in drug abuse // Psychopharmacology. 2008. Vol. 200(1). P. 1–26.
  119. Peskind E.R., Tsuang D.W., Bonner L.T. et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: a placebo-controlled study // Alzheimer Dis Assoc Disord. 2005. Vol. 19(1). P. 23‒28.
  120. Petty F., Davis L.L., Nugent A.L. et al. Valproate therapy for chronic combat-induced posttraumatic stress disor- der // J Clin Psychopharmacol. 2002. Vol. 22(1). P. 100‒101.
  121. Pope H.G. Jr., Kouri E.M., Hudson J.I. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: A randomized controlled trial // Archives of General Psychiatry. 2000. 57(2). P. 133–140.
  122. Qayyum A., Zai C.C., Hirata Y. et al. The role of the catechol-O-methyltransferase (COMT) gene Val158Met in aggressive behavior, a review of genetic studies // Curr Neuropharmacol. 2015. Vol. 13(6). P. 802‒814.
  123. Rabinowitz J., Avnon M., Rosenberg V. Effect of clozapine on physical and verbal aggression // Schizophr Res. 1996. Vol. 22(3). P. 249‒255.
  124. Rabinowitz1 J., Katz I.R., De Deyn P.P. et al. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone // J Clin Psychiatry. 2004. Vol. 65(10). P. 1329‒1334.
  125. Raskind M.A. Evaluation and management of aggressive behavior in the elderly demented patient // J Clin Psychiatry. 1999. Vol. 60 (Suppl 15). P. 45‒49.
  126. Ratey J.J., Leveroni C., Kilmer D. et al. The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital // J Clin Psychiatry. 1993. Vol. 54(6). P. 219‒223.
  127. Ratey J.J., Sovner R., Parks A. et al. Buspirone treatment of aggression and anxiety in mentally retarded patients: a multiple baseline, placebo lead-in study // J Clin Psychiatry. 1991. Vol. 52(4). P. 159‒161.
  128. Rubinow D.R., Schmidt P.J. Androgens, brain, and behavior // Am J Psychiatry. 1996. Vol. 153(8). P. 974‒984.
  129. Saïas T., Gallarda T. [Paradoxical aggressive reactions to benzodiazepine use: a review]. [Article in French] // Encephale. 2008. Vol. 34(4). P. 330‒336.
  130. Samaha A.N. Can antipsychotic treatment contribute to drug addiction in schizophrenia? // Prog Neuropsychopharmacol Biol Psychiatry. 2014. Vol. 52. P. 9‒16.
  131. Schmidt R., Baumhackl U., Berek K. et al. [Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria]. [Article in German] // Neuropsychiatr. 2010. Vol. 24(2). P. 125‒131.
  132. Shankle W.R., Nielson K.A., Cotman C.W. Low-dose propranolol reduces aggression and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients // Alzheimer Dis Assoc Disord. 1995. Vol. 9(4). P. 233‒237.
  133. Sheard M.H., Marini J.L., Bridges C.I. et al. The effect of lithium on impulsive aggressive behavior in man // Am J Psychiatry. 1976. Vol. 133(12). P. 1409‒1413.
  134. Shehata G.A., Bateh A.E.M., Hamed S.A. et al. Neuropsychological effects of antiepileptic drugs (carbamazepine versus valproate) in adult males with epilepsy // Neuropsychiatr Dis Treat. 2009. Vol. 5. P. 527‒533.
  135. Siever L.J. Neurobiology of aggression and violence // Am J Psychiatry. 2008. Vol. 165(4). P. 429‒442.
  136. Sinzig J., Döpfner M.,Lehmkuhl G.; German Methylphenidate Study Group et al. Long-acting methylphenidate has an effect on aggressive behavior in children with attention-deficit/hyperactivity disorder // J Child Adolesc Psychopharmacol. 2007. Vol. 17(4). P. 421‒432.
  137. Skodol A.E. Longitudinal course and outcome of personality disorders // Psychiatr Clin N Am. 2008. Vol. 31(3). P. 495–503.
  138. Soderstrom H., Tullberg M., Wikkelso C. et al. Reduced regional cerebral blood flow in non-psychotic violent offenders // Psychiatry Research. 2000. Vol. 98(1). P 29–41.
  139. Sorgi P.J., Ratey J.J., Polakoff S. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia // Am J Psychiatry. 1986. Vol. 143(6). P. 775‒776.
  140. Stanford M.S., Anderson N.E., Lake S.L., Baldridge R.M. Pharmacologic treatment of impulsive aggression with antiepileptic drugs // Curr Treat Options Neurol. 2009. Vol. 11(5). P. 383‒390.
  141. Stevenson J., Meares R., Comerford A. Diminished impulsivity in older patients with borderline personality disor- der // Am J Psychiatry. 2003. Vol. 160(1). P. 165‒166.
  142. Sumer M.M., Atik L., Unal A. et al. Frontal lobe epilepsy presented as ictal aggression // Neurol Sci. 2007. Vol. 28(1). P. 48‒51.
  143. Swann A.C., Anderson J., Dougherty B.M., Moeller F.G. Measurement of interepisode impulsivity in bipolar disorder: preliminary report // Psychiatr Res. 2001. Vol. 101(2). P. 195‒197.
  144. Swann A.C., Dougherty D.M., Pazzaglia P.J. et al. Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder // Am J Psychiatry. 2005. Vol. 162(9). P. 1680–1687.
  145. Tariot P.N., Raman R., Jakimovich L. et al. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial // Am J Geriatr Psychiatry. 2005. Vol. 13(11). P. 942‒949.
  146. Torregrossa M.M., Quinn J.J., Taylor, J.R. Impulsivity, compulsivity and habit: the role of orbitofrontal cortex revisited // Biol Psychiatry. 2008. Vol. 63(3). P. 253‒255.
  147. Tyrer P., Seivewright H. The stability of personality disorders // Psychiatry. 2005. Vol. 4(3). P. 29–31.
  148. Vartiainen H., Tiihonen J., Putkonen A. et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia // Acta Psychiatr Scand. 1995. Vol. 91(5). P. 348‒351.
  149. Vasudev A., Macritchie K., Vasudev K. et al. Oxcarbazepine for acute affective episodes in bipolar disorder // Cochrane Database Syst Rev. 2011. (12): CD004857.
  150. Versace A., Almeida J.R., Quevedo K. et al. Right orbitofrontal corticolimbic and left corticocortical white matter connectivity differentiate bipolar and unipolar depression // Biol Psychiatry. 2010. Vol. 68(6). P. 560–567.
  151. Virkkunen M., Goldman D., Nielsen D.A., Linnoila M. Low brain serotonin turnover rate (low CSF 5-HIAA) and impulsive violence // J Psychiatry Neurosci. 1995. Vol. 20(4). P. 271–275.
  152. Volavka J., Czobor P., Nolan K. et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol // J Clin Psychopharmacol. 2004. Vol. 24(2). P. 225‒228.
  153. Volkow N., Chang L., Wang G.J. et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex // Am J Psychiatry. 2001. Vol. 158(12). P. 2015–2021.
  154. Wang P.S., Schneeweiss S., Avorn J. et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications // N Engl J Med. 2005. Vol. 353(22). P. 2335‒2341.
  155. Wilcock G.K., Ballard C.G., Cooper J.A., Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies // J Clin Psychiatry. 2008. Vol. 69(3). P. 341‒348.
  156. Wilson J.P., Zigelbaum D. PTSD and disposition to criminal behavior // Trauma and it’s wake. Vol. 2. Traumatic stress: research, theory and intervention [Ed. Ch. R. Figley]. New York: Brunner & Mazel, 1986. P. 305‒321.
  157. Winstanley C.A., Theobald D.E., Dalley J.W. et al. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity interactions with global 5-HT depletion // Psychopharmacology (Berl). 2004. Vol. 176(3-4). P. 376‒385.
  158. Wise R.A. Dopamine and reward: The anhedonia hypothesis 30 years on // Neurotox Research. 2008. Vol. 14(2-3). P. 169‒183.
  159. Wood R.L., Thomas R.H. Impulsive and episodic disorders of aggressive behaviour following traumatic brain injury // Brain Inj. 2013. Vol. 27(3). P. 253–261.
  160. Yehuda R. Managing anger and aggression in patients with posttraumatic stress disorder // J Clin Psychiatry. 1999. Vol. 60 (Suppl 15). P. 33‒37.
  161. Yudofsky S, Williams D, Gorman J. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndromes // Am J Psychiatry. 1981. Vol. 138(2). P. 218‒220.
  162. Zimmet S.V., Strous R.D., Burgess E.S. et al. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey // J Clin Pharmacol. 2000. Vol. 20(1). P. 94–98.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2023 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 75562 от 12 апреля 2019 года.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies